Published in Diabetes Care on December 29, 2008
A Trial of BMS-512148 in Patients With Type 2 Diabetes Mellitus | NCT00263276
Effectiveness of Dapagliflozin for Weight Loss | NCT03968224
Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int (2013) 5.20
Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care (2010) 4.67
SGLT2 inhibition--a novel strategy for diabetes treatment. Nat Rev Drug Discov (2010) 4.22
A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care (2009) 3.50
Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care (2011) 2.96
SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function. Diabetes (2011) 2.23
Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care (2012) 2.17
Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One (2012) 2.01
Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications. Diabet Med (2010) 1.92
Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes Metab (2013) 1.85
The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol (2014) 1.75
SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol (2012) 1.73
Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care (2013) 1.58
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med (2013) 1.55
Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab (2013) 1.50
Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. Metabolism (2011) 1.41
Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes (2012) 1.38
Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus. J Diabetes Investig (2013) 1.34
Metformin: an old but still the best treatment for type 2 diabetes. Diabetol Metab Syndr (2013) 1.31
SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes (2013) 1.30
LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther (2012) 1.21
Year in diabetes 2012: The diabetes tsunami. J Clin Endocrinol Metab (2012) 1.19
Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. Drug Des Devel Ther (2014) 1.14
Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther (2013) 1.11
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol (2011) 1.09
Dapagliflozin as monotherapy or combination therapy in Japanese patients with type 2 diabetes: an open-label study. Diabetes Ther (2014) 1.08
Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. Diabetes Care (2014) 1.07
Renal hyperfiltration related to diabetes mellitus and obesity in human disease. World J Diabetes (2012) 1.06
Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy. Diabetes Care (2014) 0.99
Renal glucose transporters: novel targets for hyperglycemia management. Nat Rev Nephrol (2010) 0.98
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol (2015) 0.98
Sodium Glucose Co-transporter Type 2 (SGLT2) Inhibitors: Targeting the Kidney to Improve Glycemic Control in Diabetes Mellitus. Diabetes Ther (2013) 0.98
Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis. Cardiovasc Diabetol (2016) 0.96
Targeting the kidney and glucose excretion with dapagliflozin: preclinical and clinical evidence for SGLT2 inhibition as a new option for treatment of type 2 diabetes mellitus. Diabetes Metab Syndr Obes (2012) 0.95
Assessing Bladder Cancer Risk in Type 2 Diabetes Clinical Trials: the Dapagliflozin Drug Development Program as a 'Case Study'. Diabetes Ther (2015) 0.94
Medical decision support using machine learning for early detection of late-onset neonatal sepsis. J Am Med Inform Assoc (2013) 0.93
Sodium glucose co-transport 2 inhibitors in the treatment of type 2 diabetes mellitus: a meta-analysis of randomized double-blind controlled trials. BMC Endocr Disord (2013) 0.92
Renal effects of dapagliflozin in patients with type 2 diabetes. Ther Adv Endocrinol Metab (2014) 0.91
Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes (2012) 0.91
Dapagliflozin's Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension. Diabetes Care (2015) 0.90
Carcinogenicity risk assessment supports the chronic safety of dapagliflozin, an inhibitor of sodium-glucose co-transporter 2, in the treatment of type 2 diabetes mellitus. Diabetes Ther (2014) 0.90
Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition. Indian J Endocrinol Metab (2013) 0.89
Pharmacokinetics, Pharmacodynamics, and Safety of Luseogliflozin in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized, Single-blind, Placebo-controlled Trial. Adv Ther (2015) 0.89
Remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2, improves serum glucose profiles in type 1 diabetes. Diabetes Care (2012) 0.88
SGLT-2 Inhibitors: A New Mechanism for Glycemic Control. Clin Diabetes (2014) 0.87
SGLT-2 inhibitors in development for type 2 diabetes treatment. Rev Diabet Stud (2011) 0.87
Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes. Diabetes Ther (2011) 0.87
Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial. Adv Ther (2014) 0.87
Development and potential role of type-2 sodium-glucose transporter inhibitors for management of type 2 diabetes. Diabetes Ther (2011) 0.86
Limitations and future treatment options in type 2 diabetes with renal impairment. Diabetes Care (2011) 0.86
Combination of the sodium-glucose cotransporter-2 inhibitor empagliflozin with orlistat or sibutramine further improves the body-weight reduction and glucose homeostasis of obese rats fed a cafeteria diet. Diabetes Metab Syndr Obes (2014) 0.86
Pharmacodynamic model of sodium-glucose transporter 2 (SGLT2) inhibition: implications for quantitative translational pharmacology. AAPS J (2011) 0.85
Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebo-controlled trial. Diabetes Ther (2014) 0.85
Current therapies and emerging drugs in the pipeline for type 2 diabetes. Am Health Drug Benefits (2011) 0.84
The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system. Diab Vasc Dis Res (2014) 0.84
Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review. Osteoporos Int (2015) 0.83
Diabetic nephropathy - Epidemiology in Asia and the current state of treatment. Indian J Nephrol (2011) 0.83
Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus. Am J Physiol Renal Physiol (2015) 0.83
Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan. World J Diabetes (2015) 0.81
Basal-Supported Oral Therapy with Sitagliptin Counteracts Rebound Hyperglycemia Caused by GLP-1 Tachyphylaxis. Int J Endocrinol (2014) 0.81
Potential for combination of dipeptidyl peptidase-4 inhibitors and sodium-glucose co-transporter-2 inhibitors for the treatment of type 2 diabetes. Diabetes Obes Metab (2015) 0.80
Patient considerations in the management of type 2 diabetes - critical appraisal of dapagliflozin. Patient Prefer Adherence (2014) 0.80
Morning Spot Urine Glucose-to-Creatinine Ratios Predict Overnight Urinary Glucose Excretion in Patients With Type 2 Diabetes. Ann Lab Med (2017) 0.79
Update on the treatment of type 2 diabetes mellitus. World J Diabetes (2016) 0.79
Dapagliflozin efficacy and safety: a perspective review. Ther Adv Drug Saf (2014) 0.79
Update on long-term efficacy and safety of dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab (2015) 0.78
Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. PLoS One (2016) 0.78
Novel Agents for the Treatment of Type 2 Diabetes. Diabetes Spectr (2014) 0.78
Evaluation of the effect of dapagliflozin on cardiac repolarization: a thorough QT/QTc study. Diabetes Ther (2011) 0.78
Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline Data. J Clin Med Res (2017) 0.78
Dapagliflozin, a Sodium-Glucose Co-Transporter 2 Inhibitor, Acutely Reduces Energy Expenditure in BAT via Neural Signals in Mice. PLoS One (2016) 0.77
Diabetic Kidney Disease: Pathophysiology and Therapeutic Targets. J Diabetes Res (2015) 0.77
Serum uric acid and disorders of glucose metabolism: the role of glycosuria. Braz J Med Biol Res (2014) 0.77
A novel strategy for the treatment of diabetes mellitus - sodium glucose co-transport inhibitors. N Am J Med Sci (2010) 0.77
The Use of SGLT-2 Inhibitors in Type 2 Diabetes and Heart Failure. Metab Syndr Relat Disord (2015) 0.77
The management of type 2 diabetic patients with hypoglycaemic agents. ISRN Endocrinol (2012) 0.77
Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes. Core Evid (2012) 0.77
Novel and emerging diabetes mellitus drug therapies for the type 2 diabetes patient. World J Diabetes (2014) 0.77
Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data? J Clin Med (2015) 0.76
Comparison of glucose lowering effect of metformin and acarbose in type 2 diabetes mellitus: a meta-analysis. PLoS One (2015) 0.76
Long-Term Safety of Dapagliflozin in Older Patients with Type 2 Diabetes Mellitus: A Pooled Analysis of Phase IIb/III Studies. Drugs Aging (2016) 0.76
Not so critical appraisal of dapagliflozin. Patient Prefer Adherence (2014) 0.75
Differential Effects of Dapagliflozin on Cardiovascular Risk Factors at Varying Degrees of Renal Function. Clin J Am Soc Nephrol (2017) 0.75
Impact of empagliflozin in patients with diabetes and heart failure. Trends Cardiovasc Med (2016) 0.75
Impact of sodium-glucose cotransporter 2 inhibitors on blood pressure. Vasc Health Risk Manag (2016) 0.75
Dapagliflozin. Hosp Pharm (2014) 0.75
Patient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data. Diabetes Ther (2014) 0.75
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes. Sci Rep (2016) 0.75
Synthesis and SAR of Benzisothiazole- and Indolizine-β-d-glucopyranoside Inhibitors of SGLT2. ACS Med Chem Lett (2010) 0.75
Optimal Pharmacologic Treatment Strategies in Obesity and Type 2 Diabetes. J Clin Med (2014) 0.75
Dapagliflozin in patients with type 2 diabetes mellitus. Ther Adv Endocrinol Metab (2015) 0.75
Cost-Effectiveness of Dapagliflozin versus Acarbose as a Monotherapy in Type 2 Diabetes in China. PLoS One (2016) 0.75
Management of Diabetes Associated with Nephrotic Syndrome: Therapeutic Potential of Dapagliflozin for Protracted Volume Retention. Drug Target Insights (2015) 0.75
Hypouricaemia and hyperuricosuria in familial renal glucosuria. Clin Kidney J (2013) 0.75
Dapagliflozin for the treatment of type 2 diabetes: a review of the literature. Drug Des Devel Ther (2014) 0.75
Sodium glucose co-transporter inhibitors - A new class of old drugs. Int J Appl Basic Med Res (2015) 0.75
The renal effects of SGLT2 inhibitors and a mini-review of the literature. Ther Adv Endocrinol Metab (2016) 0.75
Is an Increase in Serum Magnesium One of the Causes of Cardiovascular Events Reduction in the EMPA-REG OUTCOME Study? J Clin Med Res (2017) 0.75
An overview of the effect of sodium glucose cotransporter 2 inhibitor monotherapy on glycemic and other clinical laboratory parameters in type 2 diabetes patients. Ther Clin Risk Manag (2016) 0.75
A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med (1999) 82.86
10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med (2008) 35.49
Islet beta cell failure in type 2 diabetes. J Clin Invest (2006) 7.67
Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA (2007) 6.40
Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem (2008) 5.15
Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest (1987) 4.26
Active sugar transport in health and disease. J Intern Med (2007) 3.44
The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest (1994) 3.30
Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats. Diabetes (2008) 2.58
Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol (2003) 2.34
Molecular physiology of sodium-glucose cotransporters. Physiol Rev (1994) 2.06
Effect of diabetes and insulin of the maximum capacity of the renal tubules to reabsorb glucose. J Clin Invest (1951) 2.04
Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2). Hum Genet (2002) 1.51
Diabetes-associated macrovasculopathy: pathophysiology and pathogenesis. Diabetes Obes Metab (2007) 1.33
Risk of macrovascular and microvascular complications in Type 2 diabetes: results of longitudinal study design. J Diabetes Complications (2002) 1.29
Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest (1991) 1.28
Pathophysiology and treatment of diabetic peripheral neuropathy: the case for diabetic neurovascular function as an essential component. Curr Diabetes Rev (2006) 1.28
Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal. Diabetes (1984) 1.27
Incidence and risk factors associated with urinary tract infection in diabetic patients with and without asymptomatic bacteriuria. Eur J Clin Microbiol Infect Dis (2006) 1.23
State of diabetes care in the United States. Am J Manag Care (2007) 1.06
Phlorizin induces lipolysis and alters meal patterns in both early- and late-lactation dairy cows. J Dairy Sci (2007) 0.98
Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care (2010) 4.67
A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care (2009) 3.50
Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med (2012) 3.38
Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. Kidney Int (2002) 2.35
Malignant hypertension in patients treated with vascular endothelial growth factor inhibitors. J Clin Hypertens (Greenwich) (2012) 2.03
The 2007 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2007) 2.01
The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2012) 1.86
The 2013 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol (2013) 1.85
Laboratory assays for Epstein-Barr virus-related disease. J Mol Diagn (2008) 1.82
Type 2 diabetes mellitus management in Canada: is it improving? Can J Diabetes (2013) 1.75
The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults. AIDS (2004) 1.73
Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial. J Am Soc Nephrol (2003) 1.70
A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med (2010) 1.70
Using Epstein-Barr viral load assays to diagnose, monitor, and prevent posttransplant lymphoproliferative disorder. Clin Microbiol Rev (2010) 1.68
Hypoglycemia. Can J Diabetes (2013) 1.57
A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol (2010) 1.50
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2010) 1.44
The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 2--therapy. Can J Cardiol (2009) 1.42
Role of HCN channels in neuronal hyperexcitability after subarachnoid hemorrhage in rats. J Neurosci (2012) 1.42
The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol (2011) 1.38
Pharmacologic management of type 2 diabetes. Can J Diabetes (2013) 1.34
New pollen-specific receptor kinases identified in tomato, maize and Arabidopsis: the tomato kinases show overlapping but distinct localization patterns on pollen tubes. Plant Mol Biol (2002) 1.31
The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2 - therapy. Can J Cardiol (2008) 1.25
Obesity, proteinuria and progression of renal failure. Curr Opin Nephrol Hypertens (2006) 1.25
Mutations in theCOL4A4 and COL4A3 genes cause familial benign hematuria. J Am Soc Nephrol (2002) 1.16
p63 expression in normal, hyperplastic and malignant breast tissues. Breast Cancer (2002) 1.13
Harmonization of guidelines for the prevention and treatment of cardiovascular disease: the C-CHANGE Initiative. CMAJ (2011) 1.12
Endovascular treatment of very small intracranial aneurysms. Surg Neurol (2008) 1.11
Monitoring glycemic control. Can J Diabetes (2013) 1.10
Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med (2004) 1.10
An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J Virol (2012) 1.10
Factors that determine an incomplete recovery of renal function in macrohematuria-induced acute renal failure of IgA nephropathy. Clin J Am Soc Nephrol (2006) 1.08
Factors influencing the progression of renal damage in patients with unilateral renal agenesis and remnant kidney. Kidney Int (2005) 1.07
Long-term renal survival in malignant hypertension. Nephrol Dial Transplant (2010) 1.05
VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod Pathol (2005) 1.04
Epstein-Barr virus-specific methylation of human genes in gastric cancer cells. Infect Agent Cancer (2010) 1.04
Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol (2014) 1.01
Strand-specific RNA-seq reveals widespread occurrence of novel cis-natural antisense transcripts in rice. BMC Genomics (2012) 0.98
Renal damage associated with proteinuria. Kidney Int Suppl (2002) 0.96
Development of a method for bacteria and virus recovery from heating, ventilation, and air conditioning (HVAC) filters. J Environ Monit (2006) 0.95
Surgical extraction of migrated coils via proximal segment of the anterior cerebral artery: an emergency alternative. Neurol India (2009) 0.91
Gastrointestinal stromal tumors: are they of cajal cell origin? Exp Mol Pathol (2002) 0.88
Biotemplated preparation of CdS nanoparticles/bacterial cellulose hybrid nanofibers for photocatalysis application. J Hazard Mater (2011) 0.87
Efficient bulk heterojunction solar cells with poly[2,7-(9,9-dihexylfluorene)-alt-bithiophene] and 6,6-phenyl C61 butyric acid methyl ester blends and their application in tandem cells. ACS Appl Mater Interfaces (2010) 0.87
Dithienothiophene (DTT)-based dyes for dye-sensitized solar cells: synthesis of 2,6-dibromo-DTT. J Org Chem (2011) 0.84
Adenosine A3 receptor agonist reduces early brain injury in subarachnoid haemorrhage. Neuroreport (2010) 0.84
LMP1-deficient Epstein-Barr virus mutant requires T cells for lymphomagenesis. J Clin Invest (2014) 0.82
Synthesis and application of single-isomer 6-mono(alkylimidazolium)-beta-cyclodextrins as chiral selectors in chiral capillary electrophoresis. Electrophoresis (2005) 0.82
Simultaneous improvement in short circuit current, open circuit voltage, and fill factor of polymer solar cells through ternary strategy. ACS Appl Mater Interfaces (2015) 0.81
Endovascular treatment for large and giant fusiform aneurysms of the vertebrobasilar arteries. Clin Imaging (2013) 0.80
Effect of biaxial strain induced by piezoelectric PMN-PT on the upconversion photoluminescence of BaTiO₃:Yb/Er thin films. Opt Express (2014) 0.80
Improved efficiency of bulk heterojunction polymer solar cells by doping low-bandgap small molecules. ACS Appl Mater Interfaces (2014) 0.80
FGsub: Fusarium graminearum protein subcellular localizations predicted from primary structures. BMC Syst Biol (2010) 0.80
Cationic cyclodextrins chemically-bonded chiral stationary phases for high-performance liquid chromatography. Anal Chim Acta (2012) 0.80
Cinacalcet for hypercalcaemic secondary hyperparathyroidism after renal transplantation: a multicentre, retrospective, 3-year study. Nephrology (Carlton) (2014) 0.80
Effect of arsenic trioxide (ATO) on human lung carcinoma PG cell line: ATO induced apoptosis of PG cells and decreased expression of Bcl-2, Pgp. J Exp Ther Oncol (2004) 0.80
Helpful parameter for malignant potential of gastrointestinal stromal tumors (GIST). Jpn J Clin Oncol (2002) 0.80
The structural and biological properties of hydroxyapatite-modified titanate nanowire scaffolds. Biomaterials (2011) 0.79
Thyroid nodular lesion: analysis of cancer risk based on Kuma Hospital experience. Pathol Int (2003) 0.79
Methoxyethylammonium monosubstituted β-cyclodextrin as the chiral selector for enantioseparation in capillary electrophoresis. J Chromatogr A (2012) 0.79
Hydroxyethylammonium monosubstituted cyclodextrin as chiral selector for capillary electrophoresis. Anal Chim Acta (2013) 0.79
Effects of oral paricalcitol on secondary hyperparathyroidism and proteinuria of kidney transplant patients. Transplantation (2013) 0.78
Dural arteriovenous fistula of the anterior cranial fossa associated with a ruptured ophthalmic aneurysm: case report and review of the literature. Surg Neurol (2007) 0.78
Lipid effects of glyburide/metformin tablets in patients with type 2 diabetes mellitus with poor glycemic control and dyslipidemia in an open-label extension study. Clin Ther (2002) 0.78
Obesity-related renal damage: changing diet to avoid progression. Kidney Int (2010) 0.78
Finely tuning metallic nanogap size with electrodeposition by utilizing high-frequency impedance in feedback. Angew Chem Int Ed Engl (2005) 0.78
Heteronanostructure of Ag particle on titanate nanowire membrane with enhanced photocatalytic properties and bactericidal activities. J Hazard Mater (2010) 0.78
Significance of hormone receptor status and tumor vessels in normal, hyperplastic and neoplastic endometrium. Pathol Int (2003) 0.77
Novel β-cyclodextrin chiral stationary phases with different length spacers for normal-phase high performance liquid chromatography enantioseparation. J Chromatogr A (2011) 0.77
Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride. Diab Vasc Dis Res (2008) 0.77
Design and photovoltaic characterization of dialkylthio benzo[1,2-b:4,5-b']dithiophene polymers with different accepting units. Phys Chem Chem Phys (2015) 0.77
Initiation and gradual intensification of premixed insulin lispro therapy versus Basal {+/-} mealtime insulin in patients with type 2 diabetes eating light breakfasts. Diabetes Care (2013) 0.77
Color image analysis of cervical neoplasia using RGB computer color specification. Anal Quant Cytol Histol (2002) 0.77
The Presence of Pretransplant Antiphospholipid Antibodies IgA Anti-β-2-Glycoprotein I as a Predictor of Graft Thrombosis After Renal Transplantation. Transplantation (2017) 0.77
Phase I clinical trial of valacyclovir and standard of care cyclophosphamide in children with endemic Burkitt lymphoma in Malawi. Clin Lymphoma Myeloma Leuk (2012) 0.76
Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes. Diab Vasc Dis Res (2009) 0.76
Weight loss and proteinuria. Contrib Nephrol (2006) 0.76
Epstein-Barr virus latent membrane protein 1 is not associated with vessel density nor with hypoxia inducible factor 1 alpha expression in nasopharyngeal carcinoma tissue. Head Neck Pathol (2009) 0.76
Policies, Guidelines and Consensus Statements: Pharmacologic Management of Type 2 Diabetes-2015 Interim Update. Can J Diabetes (2015) 0.76
First-principles study of half-metallicity in semi-hydrogenated BC3, BC5, BC7, and B-doped graphone sheets. Nanoscale Res Lett (2011) 0.76
Assessing the impact of a new delivery method of insulin on glycemic control using a novel trial design. Diabetes Metab Syndr Obes (2009) 0.75
Three Molecular Subtypes of Gastric Adenocarcinoma Have Distinct Histochemical Features Reflecting Epstein-Barr Virus Infection Status and Neuroendocrine Differentiation. Appl Immunohistochem Mol Morphol (2015) 0.75
Reply to vascular endothelial growth factor: a novel potential therapeutic target for hypertension. J Clin Hypertens (Greenwich) (2013) 0.75
Mono-6A-(4-methoxybutylamino)-6A-β-cyclodextrin as a chiral selector for enantiomeric separation. J Sep Sci (2014) 0.75
PKGIα inhibits the proliferation of cerebral arterial smooth muscle cell induced by oxyhemoglobin after subarachnoid hemorrhage. Acta Neurochir Suppl (2011) 0.75
Improved permeability and selectivity in porous graphene for hydrogen purification. Phys Chem Chem Phys (2014) 0.75
Novel cyclodextrin chiral stationary phases for high performance liquid chromatography enantioseparation: effect of cyclodextrin type. J Chromatogr A (2011) 0.75
Enhanced performance of polymer solar cells by employing a ternary cascade energy structure. Phys Chem Chem Phys (2014) 0.75
A family of single-isomer, dicationic cyclodextrin chiral selectors for capillary electrophoresis: mono-6(A)-ammonium-6(C)-butylimidazolium-β-cyclodextrin chlorides. Electrophoresis (2013) 0.75
Hypoglycemia. Can J Diabetes (2015) 0.75
Necrotizing Thrombophlebitis Secondary to Mycobacterium Chelonae in a Hemodialyzed Patient. Am J Dermatopathol (2017) 0.75
Cationic cyclodextrin as versatile chiral selector for enantiomeric separation in capillary electrophoresis. J Chromatogr A (2012) 0.75
Development of a laser synthetic wavelength interferometer for large displacement measurement with nanometer accuracy. Opt Express (2010) 0.75
Electrochemical behavior of gold nanoparticles modified nitrogen incorporated tetrahedral amorphous carbon and its application in glucose sensing. J Nanosci Nanotechnol (2011) 0.75
A dural arteriovenous fistula of the anterior cranial fossa angiographically mimicking an anterior ethmoidal artery aneurysm. J Neuroimaging (2010) 0.75
Evaluation of the chiral separation ability of single-isomer cationic β-cyclodextrins in capillary electrophoresis. Electrophoresis (2014) 0.75
Design and photovoltaic characterization of dithieno[3,2-b:2',3'-d]silole copolymers with positioning phenyl groups. Phys Chem Chem Phys (2014) 0.75